



Serology-based SARS-CoV-2 Total Antibody Detection ELISA Assay

Eurofins Ingenasa has been involved in the development of diagnostic tests supporting the control of infectious diseases for over 35 years in veterinary and more recently in human diagnostics.

With the COVID-19 outbreak, our efforts are focused on the development of unique and highly reliable diagnostic tools for the detection of the novel coronavirus SARS-CoV-2.

Total Antibody Detection in one ELISA assay

The **CE-IVD marked INgezim COVID 19 DR** is a dual recognition enzyme-linked immunosorbent assay (ELISA) capable of detecting total SARS-CoV-2 virus N-protein-specific antibodies (IgG, IgM and IgA) in a single human serum or plasma sample.

The assay is highly sensitive and specific to SARS-CoV-2.

Serology-based SARS-CoV-2 Total Antibody Detection ELISA Assay



Application

The **INgezim COVID 19 DR ELISA** is designed to semi-quantitatively determine total SARS-CoV-2 virus N-protein-specific antibodies (IgG, IgA and IgM) in human serum or plasma samples.

The **INgezim COVID assays** use the SARS-CoV-2 nucleoprotein (N protein) as the antigen for the detection of antibodies to SARS-CoV-2. The N protein is one of the most abundant early-onset proteins of the virus, as well as being highly immunogenic and therefore a good candidate antigen for the diagnosis of COVID 19.

Validation

The analytical sensitivity of the assay is 100% from day 17 after symptoms onset (85% between days 7 and 16).

The diagnostic specificity of the assay is 99%. There is no cross-reactivity with other respiratory coronaviruses (229E, NL63, OC43 and HKU1) and no interferences have been found for antibodies for respiratory viruses such as Influenza or RSV.*

**The results have been validated on a panel of 332 well referenced sera samples.*



INgezim COVID 19 DR

- Double recognition ELISA for the determination of total antibodies in serum samples. Capable of detecting all isotypes (IgG, IgM and IgA) in a single sample
 - Particularly recommended for the early detection of SARS-CoV-2 specific antibodies
- Total incubation: 1 hour and 15 minutes
- No sample pre-dilution required
- Compatible with various open platform ELISA analyzers
- CE-IVD marked

Art. No.	Product	No. of tests	Product description
50.CoV.K.0/5	INgezim COVID 19 DR	480	Double recognition ELISA for the determination of total antibodies in serum samples.